BDBM325506 (1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl)pyrazolo[1,5-a]pyrazin- 6-yl)-1H-pyrazol-1- yl)cyclobutanecarboxamide::US10189845, Example 168::US10730880, Example 168::US11028093, Example 168

SMILES CCC(CC)n1cc(cn1)-c1nc(cn2nccc12)-c1cnn(c1)C1C[C@@H](C1)C(N)=O

InChI Key InChIKey=QXNBQQFEJLEJRY-WWMQWHJHSA-N

Data  16 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 16 hits for monomerid = 325506   

TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  550nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK3 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit Tyk2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  55nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK2 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM325506((1s,3s)-3-(4-(4-(1-(pentan- 3-yl)-1H-pyrazol-4- yl...)
Affinity DataIC50:  5.50E+3nMAssay Description:Compounds of Formula I were screened for their ability to inhibit JAK1 using the general enzyme inhibition assay method, in which the assay mixture c...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent